Maria Inmaculada
Heras Fernando
Asociado Ciencias de la Salud
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublications in collaboration with researchers from Hospital de la Santa Creu i Sant Pau (22)
2024
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation
-
Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC
Transplantation, Vol. 108, Núm. 10, pp. 2134-2143
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
-
Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain
Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8
-
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94
2023
2022
-
CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S440-S441
2021
-
Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers
Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8
-
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928
-
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group
Transplant Infectious Disease, Vol. 23, Núm. 4
-
Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment
Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290
-
Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group
American Journal of Transplantation, Vol. 21, Núm. 1, pp. 258-271
2017
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
-
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59
2015
-
Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: Improving outcomes over time
Bone Marrow Transplantation, Vol. 50, Núm. 2, pp. 274-281
-
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: Results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH)
Transplant Infectious Disease, Vol. 17, Núm. 2, pp. 221-233
2013
-
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML
Leukemia, Vol. 27, Núm. 11, pp. 2157-2164
-
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients
British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482
2010
-
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group
Haematologica, Vol. 95, Núm. 4, pp. 589-596